Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHS-1031 Adjunctive to PPI Therapy for GERD
NCT05556824Phase 2Completed
- Sponsor
- Microbiome Health Sciences
- Start
- Mar 2023
- Primary completion
- May 2026
- Modality
- Microbiome Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MHS-1031 in gastroesophageal reflux disease (GERD), sponsored by Microbiome Health Sciences. Started Mar 2023; status: completed.
02
Drugs
MHS-1031
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05556824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556824.